JianXin (Beijing)

JianXin (Beijing) is a fund that appears to operate as a strategic investor and direct equity investor in Chinese technology and healthcare companies. The entity is cited as "建信（北京）投资" or "建信投资" in deal announcements, indicating it is a Beijing-based investment arm of China Construction Bank's asset management platform.

Its disclosed portfolio includes several growth-stage companies across sectors: it participated in Machenike's Series B+ round in 2023 as one of multiple institutional backers , joined a nearly RMB 400 million Series B+ for photonics firm Kunyao Optoelectronics in 2021 alongside Source Code Capital and others , and invested in Haichang Biotech's nearly 500 million yuan Series C round in 2025, which was structured as part of a "national capital strategic leadership" matrix alongside SDIC Venture Capital and others . It has also been described as a "strategic partner" to JD Energy, providing capital and resource access rather than pure financial investment .

The fund's activity clusters in hard technology (robotics, photonics, energy storage) and biotech, typically entering at Series B or later alongside both state-affiliated and private venture firms. elsewhere's corpus does not contain its founding date, AUM, or detailed strategy beyond these deal participations.